What is the current stock price of Editas Medicine, Inc. (EDIT)?

As of the latest market data, Editas Medicine, Inc. (EDIT) is trading at $2.94. The stock has seen a gain of 1.73% today.

Does Editas Medicine, Inc. (EDIT) pay a dividend?

Based on current data, Editas Medicine, Inc. does not have a confirmed active dividend policy.

What is the market cap of Editas Medicine, Inc.?

The current market capitalization of Editas Medicine, Inc. (EDIT) is approximately unavailable.

EDIT

Editas Medicine, Inc.·Healthcare

2.94

1.730%(+0.05)

Market Closed

2.97

1.020%(+0.03)

After Hours

Last Updated: — ET

52W L: $1.1852W H: $4.54

EDIT NEWS

zacks.com

2d ago

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock?

defenseworld.net

5d ago

JPMorgan Chase & Co. Has $2.85 Million Position in Editas Medicine, Inc. $EDIT

JPMorgan Chase and Co. cut its holdings in Editas Medicine, Inc. (NASDAQ: EDIT) by 23.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 820,667 shares of the company's stock after selling 245,055 shares during the period. JPMorgan Chase

globenewswire.com

Mar 27

Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference

CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office reaffirmed the Patent Trial and Appeal Board's (PTAB's) previous decision favoring the Broad Institute in the U.S. patent interference involving specific patents for CRISPR/Cas9 editing in human cells between the University of California, the University of Vienna, and Emmanuelle Charpentier (collectively, CVC) and the Broad Institute, Massachusetts Institute of Technology (MIT), and Harvard University (collectively, Broad).

defenseworld.net

Mar 19

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Editas Medicine, Inc. (NASDAQ: EDIT - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one

fool.com

Mar 17

Is Editas Medicine Going to $0?

Editas Medicine has been on fire over the trailing-12-month period. However, the stock has been crushed since 2021, as it has faced plenty of setbacks.

seekingalpha.com

Mar 12

Editas Medicine, Inc. (EDIT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

246

IPO Date

2016-02-03

Beta

2.04

Websitewww.editasmedicine.com↗